houston, we (almost) have liftoff

Houston company prepares for takeoff of first commercial space launch

Four commercial astronauts are headed to the ISS this week, thanks to a Houston tech company. Photo courtesy Axiom Space

A Houston-based space tech company has been preparing for liftoff, and all signs point to moving forward with the planned launch tomorrow, April 8.

Axiom Space’s first mission — Axiom mission 1 (Ax-1) headed to the International Space Station on SpaceX machinery — is ready for takeoff. SpaceX, Axiom, and NASA are targeting a launch time of 10:17 a.m. Docking is expected to occur Saturday, April 9, at around 6:30 a.m. Axiom will be airing a lifestream of the launch on its website.

Axiom Space, which reached $1 billion valuation and joined the Houston unicorn club last year after a $130 million investment round, is working on the first commercial space station to replace the ISS. The first launch of that mission is expected in late 2024. In the meantime, Axiom has a series of commercial launches to the existing station currently in orbit in order to prepare for development and orchestration of Axiom Station.

"This really represents the first step where a bunch of individuals who want to do something meaningful in low earth orbit that aren't members of the government are able to take this opportunity," says Michael Suffredini, president and CEO of Axiom Space, at a recent press conference. "It's really a precursor mission to a fully commercial space station that we're developing."

SpaceX’s Dragon spacecraft arrived last week in the hangar at Launch Complex 39A at NASA’s Kennedy Space Center in Florida and, according to a news release from Axiom, the spacecraft has since been mated with the Falcon 9 rocket.

On the 10-day mission, the Ax-1 crew will spend eight days on the ISS conducting research and testing technology and operations. The mission's members include:

  • Commander Michael López-Alegría of Spain and the United States
  • Pilot Larry Connor of the United States
  • Mission Specialist Eytan Stibbe of Israel
  • Mission Specialist Mark Pathy of Canada

"This mission is important because not only are we're also developing the techniques we will be using communication from mission control to space, but we're also developing all the procedures and processes that make space travel possible," says Peggy Whitson, director of Human Space Flight at Axiom Space, at the news conference.


Part of Axiom's long-term plans include an Earth observatory of its commercial space station. Photo via axiomspace.com

Trending News

Building Houston

 
 

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


Trending News